Geron
Open
$1.14
Prev. Close
$1.14
High
$1.15
Low
$1.14
Market Snapshot
$736.63M
-10.9
-0.27
$76.99M
258
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 258 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 258 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Recently from Cashu
Avaí Bio Advances Anti-Aging Therapies with New Production Standards and Strategic Partnerships
Avaí Bio Sets New Standards in Anti-Aging Therapy Production Avaí Bio, Inc., a prominent figure in the biotechnology sector, is making important strides in the anti-aging therapy market, which is pois…
Avaí Bio Leads Growth in Anti-Aging Therapy Market, Targeting $420 Billion by 2030
Avaí Bio Positions Itself at the Forefront of the Anti-Aging Therapy Market Avaí Bio, Inc., a biotechnology company that specializes in cell-based therapies targeting diabetes and age-related disorder…
Avaí Bio's Strategic Focus on Anti-Aging Therapies in Expanding Global Market
Avaí Bio's Strategic Initiative in Anti-Aging Therapies Avaí Bio, Inc. stands at the vanguard of the burgeoning global anti-aging therapy market, a sector expected to surpass $420 billion by 2030. Thi…
Geron Corporation Highlights Growth and Strategic Innovations in Q4 Earnings Call
Geron Corporation Reports Key Insights from Fourth Quarter Earnings Call Geron Corporation, a biopharmaceutical company focused on innovative oncology treatments, presents significant developments in…